Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
NTX-470, a novel multispecific T cell engager expressed from mRNA targets PSMA and STEAP1 prostate cancer antigens to generate enhanced functional activity. It is being evaluated for the treatment of prostate cancer.
Lead Product(s): NTX-470
Therapeutic Area: Oncology Product Name: NTX-470
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
Company will initially focus on developing first-in-class mRNA therapeutics for oncology indications and forging collaborations with biotech and pharma companies.
Lead Product(s): mRNA therapeutics
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ARCH Venture Partners
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 23, 2020